WEST LAFAYETTE, Ind., June 05, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced ...

Getting your Trinity Audio player ready... “Patients suffering from metastatic CRPC who have progressed through contemporary hormonal treatments and chemotherapy have few meaningful therapeutic ...

Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study. This ...

(RTTNews) - Swiss drug major Novartis AG (NVS) announced Tuesday positive result from its phase III VISION study evaluating the efficacy and safety of radioligand therapy 177Lu-PSMA-617 in patients ...

Men with adrenal-permissive HSD3B1 genotype and prostate cancer mortality: Results from the Veterans Affairs Health System Million Veteran Program. Parameter treated as *categorical or † continuous.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In this video, Eugene Shenderov, MD, PhD, assistant ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

EAST HANOVER, N.J., June 3, 2021 /PRNewswire/ -- Novartis today announced that results of the Phase III VISION study evaluating 177 Lu-PSMA-617, a targeted radioligand therapy, plus best standard of ...

Men who received 177 Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or ...

Men who received 177 Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or ...